The Ohio State University as a Lead Academic Organization (LAO) for the Experimental Therapeutics Clinical Trials Network

项目摘要 该项目包括一个由基础科学家和临床研究人员组成的多学科团队，致力于 为癌症患者寻找有效的新疗法。俄亥俄州州立大学综合癌症 中心（OSUCCC）是一个综合性的生物医学研究校园， 来自多个肿瘤学科的经验丰富的研究人员和基础研究领域充满活力的发现模式， 以理工科为重为了这项提案的目的，OSUCCC将与密歇根大学的研究人员合作， 肯塔基州马基癌症中心（MCC）和犹他州大学亨茨曼癌症研究所（HCI）， 他们在过去有着牢固的关系。这些网站提供了访问大量的癌症 需要接受癌症临床试验的患者，其中许多人居住在农村地区，如阿巴拉契亚或 美国西部在具有免疫治疗经验的外科医生威廉卡森博士的领导下， 和转化科学家Jennifer Woyach博士，一位血液肿瘤学家，在开发靶向 这个高度整合的团队将探索新的治疗药物和治疗方式，测试新的 基于免疫的疗法，评估耐药机制，并探索基因组分析的前景。 为了开发更有效的癌症治疗方法。值得注意的是， 几十年来，一个实验性治疗计划一直从事I/II期癌症研究 并在相关实验室研究的设计和实施方面具有丰富的经验，这些研究可以证实 新的药物击中特定的分子靶点，并定义精确的作用机制。俄亥俄州已经与 广泛与其他癌症中心致力于实验疗法，并将继续这样做， UM 1机制的背景。强大的实验室工作台研究和药理学的存在， 每个研究中心都将确保这组翻译研究者将继续为 在NCI的实验治疗药物临床试验网络（ETCTN）机制内提交。一个主要 该联盟的目标是每年增加100多名患者参加ETCTN研究，在上一个资助年度， 登记的癌症种类多种多样。对这个财团来说最重要的是教育 培训早期职业研究人员，使他们准备好领导新的翻译研究。的确， 该临床研究小组最近六项研究中的每一项都有一名早期职业研究者作为其领导者。 这个研究团队的经验，多样性和凝聚力，加上坚定不移的承诺， ETCTN的目标和原则将使其在这一令人兴奋的临床领域继续取得成功和创新。 研究机制

PROJECT SUMMARY This project encompasses a multi-disciplinary team of basic scientists and clinical investigators dedicated to finding effective new therapies for patients with cancer. The Ohio State University Comprehensive Cancer Center (OSUCCC) is a comprehensive biomedical research campus with strong collaborations between experienced investigators from multiple oncologic disciplines and a vibrant pattern of discovery in the basic sciences. For the purposes of this proposal, the OSUCCC will partner with investigators at the University of Kentucky Markey Cancer Center (MCC) and the University of Utah Huntsman Cancer Institute (HCI) with whom they have had a strong relationships in the past. These sites provide access to a large population of cancer patients that requires access to cancer clinical trials, many of whom reside in rural areas such as Appalachia or the American West. Under the leadership of Dr. William Carson, a surgeon with experience in immune therapy, and Translational Scientist Dr. Jennifer Woyach, a hematologic oncologist with skill in developing targeted therapies, this highly integrated team will explore novel therapeutic agents and treatment modalities, test new immune-based therapies, evaluate drug resistance mechanisms and explore the promise of genomic profiling of the cancer cell in order to develop more effective treatments for cancer. Notably, investigators in this experimental therapeutics program have been engaged in the conduct of phase I/II cancer studies for decades and are experienced in the design and conduct of correlative laboratory studies that can confirm the ability of a new drug to hit a specific molecular target and define a precise mechanism of action. Ohio State has collaborated extensively with other cancers centers dedicated to experimental therapeutics and will continue to do so within the context of the UM1 mechanism. The existence of strong laboratory bench research and pharmacology at each site will ensure that this group of translational investigators will continue to generate new concepts for submission within the NCI’s Experimental Therapeutics Clinical Trials Network (ETCTN) mechanism. A major goal of this consortium is to accrue over 100 patients per year to ETCTN studies and in the last grant year 102 enrollments were recorded in a variety of cancer types. Of prime importance to this consortium is the education and training of early career investigators so that they are prepared to lead new translational studies. Indeed, each of the last six studies from this clinical research group has had an early career investigator as its leader. The experience, diversity and cohesiveness of this research team combined with an unwavering commitment to ETCTN goals and principles will position it for continued success and innovation within this exciting clinical research mechanism.